The objective of this proposal is to establish and maintain the NCORP (National Cancer Institute Community Oncology Research Program) for the NRG Oncology research base. The NRG NCORP is the result of aligning the legacy CCOPs (Community Clinical Oncology Programs) from three NCI Cancer Cooperative Groups: NSABP, RTOG and GOG. These groups together have over almost 100 years of combined experience serving as CCOP Research Bases. NRG NCORP, comprised of a multi-disciplinary team of investigators and patient advocates, is poised to carry out the objectives of: 1) designing and conducting cancer prevention, control and screening clinical trials; 2) designing and embedding patient reported outcomes in therapeutic trials 3) designing and conducting cancer care delivery research; 4) enhancing community access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN) and 5) integrating disparity research questions into clinical trials and cancer care delivery research. To allow NRG NCORP to meet these goals, the group will: participate fully in NRG Oncology leadership and will determine the scientific direction and prioritization of the NRG NCORP activities and resources and oversee the translational research, clinical trial activities, and correlative studies related to the aims of NG NCORP. With the NRG Statistical and Data Management Center, this team will provide efficient, methodologically up-to-date trial design, monitoring, reporting, and analysis; build an infrastructure to support our cancer care delivery research agenda; provide comprehensive data management quality control and quality assurance programs to ensure high data integrity and timely data for analysis; leverage cutting edge information technology emphasizing security, timeliness, and efficiency of data collection and management; providing RT credentialing and quality assurance; and provide education and training for institutional Clinical Research Associates, Study Chairs, local Principal Investigators and others involved in the NRG NCORP research agenda. Further, to accomplish these aims NRG NCORP will engage fully with NCI-designated NCORP community physicians and patient advocates as well as the NCI and other NCl-sponsored entities (cooperative groups, cancer centers, SPOREs) to collaborate across the NCTN to improve cancer care and quality of life for patients affected by cancer.

Public Health Relevance

NRG Oncology is an NCI funded research group formed through the alignment of the legacy research bases of the National Surgical Adjuvant Breast Program (NSABP), the Radiation Therapy Oncology Group (RTOG) and the Gynecologic Oncology Group (GOG). NRG NCORP research will significantly impact cancer prevention, screening, control and care delivery, and bring state-of-the-art treatment trials to community centers. NRG NCORP will conduct high impact studies for patients with many types of solid tumors with a particular unique focus in both women's health and cancer control issues related to radiation therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
3UG1CA189867-04S1
Application #
9559748
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mccaskill-Stevens, Worta J
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
4
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Nrg Oncology Foundation, Inc.
Department
Type
DUNS #
078695317
City
Philadelphia
State
PA
Country
United States
Zip Code
19103
Klopp, Ann H; Yeung, Anamaria R; Deshmukh, Snehal et al. (2018) Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. J Clin Oncol 36:2538-2544
Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Seider, Michael J; Pugh, Stephanie L; Langer, Corey et al. (2018) Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Ann Nucl Med 32:553-560
Francis, Prudence A; Pagani, Olivia; Fleming, Gini F et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 379:122-137
Roach, Mack; Moughan, Jennifer; Lawton, Colleen A F et al. (2018) Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol 19:1504-1515
Regine, William F; Winter, Kathryn; Abrams, Ross A et al. (2018) Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol 3:154-162
Wapnir, Irene L; Price, Karen N; Anderson, Stewart J et al. (2018) Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol 36:1073-1079
Konski, Andre; Bhargavan, Mytheryi; Owen, Jean et al. (2018) An Economic Analysis of Radiation Therapy Oncology Group 94-10: Cost-Efficacy of Concurrent vs. Sequential Chemoradiotherapy. J Radiat Oncol 7:195-201
Shi, Wenyin; Scannell Bryan, Molly; Gilbert, Mark R et al. (2018) Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. Int J Radiat Oncol Biol Phys 100:38-44

Showing the most recent 10 out of 180 publications